Trial Profile
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide (Primary) ; Buserelin (Primary) ; Degarelix (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Histrelin (Primary) ; Leuprorelin (Primary) ; Prednisone (Primary) ; Triptorelin (Primary)
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms PREDICT-RT
- 19 Jan 2022 Planned End Date changed from 31 Dec 2038 to 31 Dec 2033.
- 19 Jan 2022 Status changed from suspended to recruiting.
- 22 Sep 2021 Status changed from recruiting to suspended (Due to design change).